Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

M.D. Egeler; M. van Leeuwen; I. Fraterman; N.M.J. van den Heuvel; A.H. Boekhout; J. Lai-Kwon; E.A. Wilthagen; H. Eriksson; J.B. Haanen; Sofie Wilgenhof; P.A. Ascierto; A.C.J. van Akkooi; L.V. van de Poll-Franse

doi:10.1016/j.critrevonc.2023.103919

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

M.D. Egeler^*, M. van Leeuwen, I. Fraterman, N.M.J. van den Heuvel, A.H. Boekhout, J. Lai-Kwon, E.A. Wilthagen, H. Eriksson, J.B. Haanen, Sofie Wilgenhof, P.A. Ascierto, A.C.J. van Akkooi, L.V. van de Poll-Franse

^*Corresponding author for this work

Medical and Clinical Psychology

Research output: Contribution to journal › Article › Scientific › peer-review

29 Downloads (Pure)

Abstract

Introduction
This systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma.

Methods
OVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included.

Results
Toxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation.

Conclusion
The toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.

Original language	English
Article number	103919
Number of pages	22
Journal	Critical Reviews in Oncology/Hematology
Volume	183
DOIs	https://doi.org/10.1016/j.critrevonc.2023.103919
Publication status	Published - 2023

Keywords

Melanoma
Adverse events
Toxicities
Immune Checkpoint Inhibitors
Targeted therapy

Access to Document

10.1016/j.critrevonc.2023.103919

MCP_vandePoll-Franse_Common toxicities associated with immune checkpoint inhibitors_CRiOH_2023Final published version, 1.49 MBLicence: Taverne

Cite this

Egeler, M. D., van Leeuwen, M., Fraterman, I., van den Heuvel, N. M. J., Boekhout, A. H., Lai-Kwon, J., Wilthagen, E. A., Eriksson, H., Haanen, J. B., Wilgenhof, S., Ascierto, P. A., van Akkooi, A. C. J., & van de Poll-Franse, L. V. (2023). Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. Critical Reviews in Oncology/Hematology, 183, Article 103919. https://doi.org/10.1016/j.critrevonc.2023.103919

@article{5eb3a502da934325a73e07267a5e0aee,

title = "Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review",

abstract = "IntroductionThis systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma.MethodsOVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included.ResultsToxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation.ConclusionThe toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.",

keywords = "Melanoma, Adverse events, Toxicities, Immune Checkpoint Inhibitors, Targeted therapy",

author = "M.D. Egeler and {van Leeuwen}, M. and I. Fraterman and {van den Heuvel}, N.M.J. and A.H. Boekhout and J. Lai-Kwon and E.A. Wilthagen and H. Eriksson and J.B. Haanen and Sofie Wilgenhof and P.A. Ascierto and {van Akkooi}, A.C.J. and {van de Poll-Franse}, L.V.",

year = "2023",

doi = "10.1016/j.critrevonc.2023.103919",

language = "English",

volume = "183",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

Egeler, MD, van Leeuwen, M, Fraterman, I, van den Heuvel, NMJ, Boekhout, AH, Lai-Kwon, J, Wilthagen, EA, Eriksson, H, Haanen, JB, Wilgenhof, S, Ascierto, PA, van Akkooi, ACJ & van de Poll-Franse, LV 2023, 'Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review', Critical Reviews in Oncology/Hematology, vol. 183, 103919. https://doi.org/10.1016/j.critrevonc.2023.103919

TY - JOUR

T1 - Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma

T2 - A systematic scoping review

AU - Egeler, M.D.

AU - van Leeuwen, M.

AU - Fraterman, I.

AU - van den Heuvel, N.M.J.

AU - Boekhout, A.H.

AU - Lai-Kwon, J.

AU - Wilthagen, E.A.

AU - Eriksson, H.

AU - Haanen, J.B.

AU - Wilgenhof, Sofie

AU - Ascierto, P.A.

AU - van Akkooi, A.C.J.

AU - van de Poll-Franse, L.V.

PY - 2023

Y1 - 2023

N2 - IntroductionThis systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma.MethodsOVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included.ResultsToxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation.ConclusionThe toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.

AB - IntroductionThis systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma.MethodsOVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included.ResultsToxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation.ConclusionThe toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.

KW - Melanoma

KW - Adverse events

KW - Toxicities

KW - Immune Checkpoint Inhibitors

KW - Targeted therapy

U2 - 10.1016/j.critrevonc.2023.103919

DO - 10.1016/j.critrevonc.2023.103919

M3 - Article

SN - 1040-8428

VL - 183

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103919

ER -

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

Abstract

Keywords

Access to Document

Fingerprint

Cite this